key: cord-1022998-ywkqya5j
authors: Romero-Ibarguengoitia, M. E.; Gonzalez-Cantu, A.; Pozzi, C.; Levi, R.; Mollura, M.; Sarti, R.; Sanz-Sanchez, M. A.; Rivera-Salinas, D.; Hernandez-Ruiz, Y. G.; Armendariz-Vazquez, A. G.; Del Rio-Parra, G. F.; Barco-Flores, I. A.; Gonzalez-Facio, R.; Azzolini, E.; Barbieri, R.; de Azevedo Dias, A. R.; Henriques-Guimaraes, M.; Bastos-Borges, A.; Acciardi, C.; Paez-Bo, G.; Teixeira, M. M.; Rescigno, M.
title: Analysis of immunization time, amplitude, and adverse events of seven different vaccines against SARS-CoV-2 across four different countries.
date: 2022-03-13
journal: nan
DOI: 10.1101/2022.03.11.22272153
sha: 6de1cd68272596721b6fd3e1dbb6359e24aefa1a
doc_id: 1022998
cord_uid: ywkqya5j

Background: Scarce information exists in relation to the comparison of seroconversion and adverse events following immunization (AEFI) with different SARS-CoV-2 vaccines. Our aim was to correlate the magnitude of the antibody response to vaccination with previous clinical conditions and AEFI. Methods: A multicentric comparative study where SARS-CoV-2 spike 1-2 IgG antibodies IgG titers were measured at baseline, 21-28 days after the first and second dose (when applicable) of the following vaccines: BNT162b2 mRNA, mRNA-1273, Gam-COVID-Vac, Coronavac, ChAdOx1-S, Ad5-nCoV and Ad26.COV2. Mixed model and Poisson generalized linear models were performed. Results: We recruited 1867 subjects [52 (SD 16.8) years old, 52% men]. All vaccines enhanced anti-S1 and anti-S2 IgG antibodies over time (p<0.01). The highest increase after the first and second dose was observed in mRNA-1273 (p<0.001). There was an effect of previous SARS-CoV-2 infection; and an interaction of age with SARS-CoV-2, Gam-COVID-Vac and ChAdOx1-S (p<0.01). There was a negative correlation of Severe or Systemic AEFI (AEs) of naive SARS-CoV-2 subjects with age and sex (p<0.001); a positive interaction between the delta of antibodies with Gam-COVID-Vac (p=0.002). Coronavac, Gam-COVID-Vac and ChAdOx1-S had less AEs compared to BNT162b (p<0.01). mRNA-1273 had a higher number of AEFIs. The delta of the antibodies showed an association with AEFIs in previously infected individuals (p<0.001). Conclusions: The magnitude of seroconversion is predicted by age, vaccine type and SARS-CoV-2 exposure. AEs are correlated with age, sex, and vaccine type. The delta of the antibody response is positively correlated with AEs in patients previously exposed to SARS-CoV-2.

Covid-19 is a pneumonia-like disease caused by a coronavirus, named SARS-CoV-2. It is highly 91 contagious, and the World Health Organization declared it in 2020 as a pandemic (1). SARS-CoV-2 92 causes COVID-19 that has a wide range of clinical presentations, from asymptomatic disease to severe 93 acute respiratory distress syndrome and death (2) . SARS-CoV-2 utilizes its surface spike glycoprotein 94 to enter host cells. Each unit of the spike trimer contains an S1 and S2 subunit, with the N-terminal S1 95 subunit binding to the cellular angiotensin-converting enzyme 2 (ACE2) receptor through an internal The inclusion criteria were volunteers of both genders, any age, who consented to participate, planned 155 to conclude the immunization regimen of any vaccine, and agreed to be followed up for the duration of 156 the study. The following vaccines were available: BNT162b2 mRNA, mRNA-1273, ChAdOx1-S, 157

Ad26.COV2, Ad5-nCoV, Gam-COVID-Vac, or Coronavac. The exclusion criteria were to have 158 received any SARS-CoV-2 vaccine prior to study entry. 159 160 Each country's Health System defined the vaccines available, the schedule, and dose assignation. On 161 the vaccination day, the research team invited any subject who planned to receive any vaccine scheme, 162 explained the project and asked to sign the informed consent. Inclusion-exclusion criteria were 163 applied, and a plasma sample was collected. The baseline sample was taken before receiving the first 164 dose of any SARS-CoV-2 vaccine (T0). The second (T1) and third samples (T2) were taken after 21 165 days (+/-7 days) of the first and second dose, respectively. 166 167 At each visit, participants had to answer a questionnaire. The basal questionnaire aimed at obtaining 168 patients' medical history and previous SARS-CoV-2 infections. The questionnaires applied after the 169 first and second dose of vaccines aimed at recognizing adverse events following immunization 170 (AEFI)(7) and identifying a potential SARS-CoV-2 infection after receiving any vaccine dose. SARS-171 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Our primary outcome was to correlate the magnitude of the antibody response to vaccination with 176 previous clinical conditions and AEs . To determine the amount of specific anti-S1 and anti-S2 IgG 177 antibodies against SARS-CoV-2 in plasma samples, the laboratory personnel used a 178 chemiluminescence immunoassay (CLIA) developed by DiaSorin, which had a sensitivity of 97.4% 179 (95% CI, 86.8-99.5) and a specificity of 98.5% (95% CI, 97.5-99.2). The results were reported as 180 follows: <12.0 AU/ml was considered negative, 12.0 to 15.0 AU/ml was indeterminate, and > 15 181 AU/ml was positive. This kit is comparable with other commercial kits and has been used elsewhere 182 (8-11). 183

The variables we analyzed were age, sex, personal medical history (for example, the presence of type 2 184 diabetes, hypertension, obstructive pulmonary disease, any heart condition, obesity, cancer, liver 185 steatosis, any autoimmune disease), and confirmed SARS-CoV-2 (through nasal swab or serologic 186 tests). The following AEs were considered of particular interest: fever (>37.5°C), adenopathy, diffuse 187 rash, edema, facial paralysis, orthostatic hypotension, headache, arthralgia, myalgia, nausea, vomit, 188 and diarrhea. Anti-S1 and anti-S2 IgG antibodies against SARS-CoV-2 were measured at baseline, 21-189 28 days post-first dose (S1), and 21-28 days post-second dose if applicable. 190

The researchers reviewed the quality control and the anonymization of the database. Normality 192 assumption was evaluated with the Shapiro-Wilk test or Kolmogorov. Descriptive statistics such as 193 mean, standard deviation, median, interquartile range, frequencies, and percentages were computed. 194

Kruskal-Wallis test with Dunn's multiple comparisons test was performed for IgG comparisons. We 195 performed a mixed model where the dependent variable was the delta of the antibodies. The personal 196 variability and time were constructed as a random effect, whereas each type of vaccine, age, history of 197 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 13, 2022. ; https://doi.org/10.1101/2022.03.11.22272153 doi: medRxiv preprint SARS-CoV-2, and the interaction of each vaccine with age were fixed effects. BNT162b mRNA was 198 the reference vaccine group. For the analysis of AEs, the study population was divided into two 199 Ad26.COV2 in 31, and Ad5-nCoV in 19. The mean (SD) age was 52 (16.8) years, being statistically 232 different across vaccine groups (p<0.05) as some vaccines were proposed to a particular age group. 233

Fifty-two % of subjects were men, 559 (30%) had obesity, and 501 (26.8%) had hypertension. Table 1  234 shows the medical history of patients divided by vaccine type. 235

Positive history of SARS-CoV-2 infection was considered if the volunteer had a confirmatory swab or 237 serological test. Additionally, it was considered if specific anti-S1 and anti-S2 IgG antibodies against 238 SARS-CoV-2 in plasma samples were > 15 AU/ml at baseline. We had a total of 627 positive cases 239 before vaccination, of which 165 (24.8%) received ChAdOx1-S, 246 (42.2%) Coronavac, 107 (37.1%) 240

BNT162b2 mRNA, 55 (25.8%) Gam-COVID-Vac, 31 (47.6%) mRNA-1273, 18 (58%) Ad26.COV2, 241 and 5 (26%) Ad5-nCoV. 242

All vaccines showed significant anti-S1 and anti-S2 IgG antibody changes with significant differences 244 across vaccines and depending on SARS-CoV-2 history. In naïve patients, the highest increase 245 (55.9)], whereas in SARS-CoV-2 previously exposed subjects the highest increase after the second 252 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Figure 1 and Figure S1 show the change in antibody levels through 254 time, classified by vaccine type. Table 2 shows the antibody levels classified by vaccine type. 255

The mixed model that showed a positive effect of SARS-CoV-2 previous infection (B=767.468, 256 p<0.001), a positive interaction of age with previous SARS-CoV-2 infection (B=13.03, p=0.003), and 257 an interaction of Gam-COVID-Vac and ChAdOx1-S with age (B=46.5, p<0.001; B=20.5; p=0.006). 258

With respect to BNT162b mRNA, mRNA-1273 showed a higher change in antibody titers, while all 259 the other vaccines had less change (p<0.01). We computed sex in the model, but there was no 260 significant correlation, so we eliminated it from the final model. These results are shown in Table 3  261 and Figure 2 . 262

At least one AEFI was observed after the first dose in 71% of respondents receiving BNT162b2 264 mRNA, in 93% with mRNA-1273, 38% with Gam-COVID-Vac, 42% with Coronavac, 51% with 265 ChAdOx1-S, 74% with Ad5-nCoV, and 81% with Ad26.COV2. After the second dose, 65%, 88%, 266 23%, 33%, and 23% of the respondents experienced at least one AEFI after receiving BNT162b2 267 mRNA, mRNA-1273, Gam-COVID-Vac, Coronavac, and ChAdOx1-S, respectively. For each 268 vaccine, the majority of the adverse events occurred during the first 24 hrs after injection, either after 269 the first or the second dose. Patients receiving BNT162b2 mRNA, mRNA-1273, Gam-COVID-Vac, 270

Coronavac, ChAdOx1-S, Ad5-nCoV, and Ad26.COV2 subjectively qualified the AEFI after the first 271 dose as "very mild" or "mild" in 85%, 80%, 95%, 84%, 67%, 93%, and 57% of cases, respectively. 272

The AEFI after the second dose were qualified as "very mild" or "mild" by 82%, 49%, 98%, 89%, and 273 76% of patients receiving BNT162b2 mRNA, mRNA-1273, Gam-COVID-Vac, Coronavac, and 274

ChAdOx1-S respectively. Finally, 49% of patients receiving mRNA-1273 qualified for their adverse 275 events after the second dose as "moderate". Figure 3 shows the percentages of AEs per vaccine. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 13, 2022.

Finally, a positive interaction was found between the delta of antibodies due to vaccination and Gam-281 COVID-Vac (B=0.5604, p=0.002). 282

The model for subjects previously exposed to SARS-CoV-2 showed a negative association of the 283 count of adverse events with age (B=-0.0190, p=0.013) and sex (B=-1.0042, p<0.001). The delta of the 284 antibodies showed a positive association with the count of adverse events (B=0.1018, p<0.001). A 285 positive effect with respect to BNT162b mRNA was observed for Gam-COVID-Vac (B=1.2737, 286 p=0.038), whereas a negative effect was observed for Coronavac (B=-1.1304, p<0.001). Negative 287 interactions were also found between the delta of antibodies due to vaccination and the vaccines Gam- CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 13, 2022. ; https://doi.org/10.1101/2022.03.11.22272153 doi: medRxiv preprint

This multicentric study compared the 21-28 day seroconversion, the AEFI after first and second doses, 310 and the associated predictors of AEs of seven of the most common vaccines used worldwide: 311

BNT162b2 mRNA, mRNA-1273, Gam-COVID-Vac, Coronavac, ChAdOx1-S, Ad5-nCoV, and 312

Ad26.COV2(4). 313

All vaccines showed immunogenicity and seroconversion after the complete vaccination scheme. The 314 greatest change in antibody levels occurred with mRNA-1273, followed by BNT162b2 mRNA and 315

Gam-COVID-Vac. Previous studies have shown a greater change in antibody titers for mRNA vector 316 vaccines(12-14). 317

Our study found that the previous history of SARS-CoV-2 was related to an increase in change in 318 antibody levels, as confirmed elsewhere (12). Also, we found higher levels in antibodies in older 319 patients when they had previous SARS-CoV-2 infection and received Gam-COVID Vac or ChAdOx1-320 S. The previous study from Brazil did not find any association of antibody levels with age. We also 321 found that except for the Gam-COVID Vac, in the other vaccines requiring two doses, the first dose 322 was sufficient to induce maximal antibody levels in subjects with a history of SARS-CoV-2, as 323 previously shown for the BNT162b2 mRNA vaccine(9,15-19) 324

The study of Logunov et older patients in our group of the study had a more severe disease during SARS-CoV-2 infection and 331 that they developed higher antibody titers, as it has been reported that patients aged higher than 60 can 332 develop this condition (21). 333 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 13, 2022. ; https://doi.org/10.1101/2022.03.11.22272153 doi: medRxiv preprint For most patients, at least one AEFI occurred with all types of vaccines during the first 24 hrs. after 334 injection, and most of them qualified the symptoms as "very mild" or "mild" both after the first and 335 second dose, except for mRNA-1273 for which nearly half of the volunteers reported moderate 336 symptoms after the second dose as reported previously(18,20,22-27). 337

Our models showed a higher risk for women and young people to experience AEs. A real-world study 338 that reported AEFI of patients receiving BNT162b2 mRNA, mRNA-1273, or Ad26COV2 in one or 339 two doses (28) On one hand, for the Naïve SARS-CoV-2 cohort, the vaccines Gam-COVID-Vac, Coronavac, and 344

ChAdOx1-S were related to fewer AEs after the second dose than BNT162b mRNA, and to the best of 345 our knowledge, there are no studies that compare AEs across these types of vaccines. Also, the delta of 346 antibodies was related to AEs after the second dose in Gam-COVID-Vac. As previously published, 347 mRNA-1273 had higher AEFIs when compared to BNT162b2 mRN(30). 348

On the other hand, for subjects previously exposed to SARS-CoV-2, those receiving Gam-COVID-349

Vac showed a greater number of AEs than BNT162b mRNA, while subjects receiving Coronavac 350 showed significantly fewer events when compared to BNT162b mRNA. In general, an increase in the 351 antibody levels was related to an increase in the number of AEFIs, but for people receiving Gam- is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 13, 2022. ; https://doi.org/10.1101/2022.03.11.22272153 doi: medRxiv preprint This study shows a low rate of infection in all vaccine groups. However, the highest rate of SARS-359

CoV-2 infection in this follow-up period was for the one-dose vaccines Ad5-nCoV and Ad26.COV2. 360

Also, Coronavac had a high rate of infection. It is important to consider that the patients were followed 361 for a short period. 362

As a limitation of our study, we recognize that we had a small sample size in some vaccine groups 363 such as Ad5-nCoV; however, to the best of our knowledge, there is no other study where this type of 364 vaccine has been compared to other types of vaccines in a real-world setting. It will be of interest to 

IgG antibody response was measured in serum of naïve and SARS-CoV-2 previously exposed (SARS-CoV-2 541 Exp) subjects at different time points (T0, T1 and T2) and vaccinated with different vaccine types. Samples vaccine type. Antibodies are expressed in logarithm and age has a Z distribution. 549 Women and young individuals developed more AEs. There is no effect on Body Mass Index. In the 553 naïve SARS-CoV-2 cohort, the vaccines Gam-COVID-Vac, Coronavac and ChAdOx1-S are related to 554 fewer AEFIs after the second dose than BNT162b mRNA. Also, for naïve SARS-CoV-2 patients who 555

received Gam-COVID-Vac, higher antibody levels after the second dose were related to a greater 556 number of AEs. In people previously exposed to SARS-CoV-2 , those receiving Gam-COVID-Vac 557

showed a greater number of AEs compared to BNT162b mRNA, while subjects receiving Coronavac 558

showed significantly fewer events when compared to BNT162b mRNA. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 13, 2022. ; https://doi.org/10.1101/2022.03.11.22272153 doi: medRxiv preprint CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 13, 2022. ; https://doi.org/10.1101/2022.03.11.22272153 doi: medRxiv preprint CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 13, 2022. ; https://doi.org/10.1101/2022.03.11.22272153 doi: medRxiv preprint 655 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 13, 2022. ; https://doi.org/10.1101/2022.03.11.22272153 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 13, 2022. ; https://doi.org/10.1101/2022.03.11.22272153 doi: medRxiv preprint

Director-General's opening remarks at the media briefing on COVID-19 -11

COVID-19 (Novel Coronavirus 2019) -418 recent trends

Morphology, Genome Organization, Replication, 421 and Pathogenesis of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Covid-19 Vaccine Tracker: Latest Updates -The New York Times

Overview of the Main Anti-SARS-CoV-429 2 Vaccines: Mechanism of Action

STROBE 432 Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) 433 statement: guidelines for reporting observational studies

Safety of SARS-CoV-2 436 vaccines: a systematic review and meta-analysis of randomized controlled trials

Clinical and Analytical Performance of an

Test That Identifies S1/S2-Neutralizing IgG in COVID-19 Patients Semiquantitatively

One dose of 443 SARS-CoV-2 vaccine exponentially increases antibodies in individuals who have recovered from 444 symptomatic COVID-19

The antibody response to SARS-CoV-2 infection persists over at least 448 8 months in symptomatic patients

Immunogenicity and Safety of the COVID-19 Vaccines Compared With 458 Control in Healthy Adults: A Qualitative and Systematic Review

Comparing the clinical efficacy of 461 COVID-19 vaccines: a systematic review and network meta-analysis

Robust spike antibody responses and 464 increased reactogenicity in seropositive individuals after a single dose of SARS-CoV-2 mRNA 465 vaccine

Antibody Responses in Seropositive 468 Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine

Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers 472 Previously Infected With SARS-CoV-2

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine 476 against Covid-19

BNT162b2 mRNA vaccine dose in SARS-CoV-2 experienced individuals

Safety and efficacy of an 483 rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis 484 of a randomised controlled phase 3 trial in Russia

Age-sex population adjusted analysis of disease severity 487 in epidemics as a tool to devise public health policies for COVID-19

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine 491 administered in a prime-boost regimen in young and old adults (COV002): a single-blind, 492 randomised, controlled, phase 2/3 trial

The dependent variable is the delta of antibodies. Time and personal variability are 602 random effects. Reference group BNT162b2 mRNA